Robert A Copeland

Title: The Innovations of Robert A. Copeland

Introduction

Robert A. Copeland is a notable inventor based in Lexington, MA (US), recognized for his significant contributions to the field of cancer research. With a total of four patents to his name, he has made strides in developing innovative methods for treating various forms of cancer.

Latest Patents

One of his latest patents focuses on "Inhibitors of human EZH2, and methods of use thereof." This invention pertains to the inhibition of both wild-type and certain mutant forms of human histone methyltransferase EZH2, which is a crucial component of the PRC2 complex. This complex is responsible for the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). The patent highlights a selective inhibition of the mutant form of EZH2, which is associated with certain cancers. The methods described can be utilized to treat cancers such as follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Additionally, the patent outlines methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and for determining responsiveness to an EZH2 inhibitor in a subject.

Career Highlights

Robert A. Copeland is currently associated with Epizyme, Inc., where he continues to advance his research and innovations in the field of oncology. His work has been instrumental in developing targeted therapies that aim to improve patient outcomes in cancer treatment.

Collaborations

Throughout his career, Robert has collaborated with esteemed colleagues, including Victoria M. Richon and Margaret D. Scott. These collaborations have further enriched his research and contributed to the development of effective cancer therapies.

Conclusion

Robert A. Copeland's innovative work in the field of cancer research exemplifies the impact of targeted therapies on patient care. His patents and collaborations reflect a commitment to advancing medical science and improving treatment options for cancer patients.